Navigation Links
HPV vaccine could prevent breast cancer: Australian research
Date:9/3/2009

Vaccinating women against the human papillomavirus (HPV) may prevent some forms of breast cancer and save tens of thousands of lives each year, new Australian research suggests.

Using genetic probes, researchers at the University of New South Wales tested cancerous breast cells and found several strains of HPVs known to have a high risk of initiating cancer of the cervix. HPV has a causal role in 90-95 per cent of cervical cancers.

The research was conducted by a team from the UNSW School of Biotechnology and Biomolecular Sciences, led by Visiting Professor James Lawson, and is published in the British Journal of Cancer.

The team confirmed the presence of high-risk HPV in the nuclei of breast cancer epithelial cells in five (39 per cent) of 13 ductal carcinoma in situ and three (21 per cent) of 14 invasive ductal carcinoma (IDC) breast cancer specimens. Non-invasive or in situ cancers are those confined to the milk-making glands and do not spread to other parts of the breast or body. Invasive cancers such as IDC are more serious and account for 70-80 percent of all breast cancers.

"The finding that high risk HPV is present in a significant number of breast cancers indicates they may have a causal role in many breast cancers," says UNSW researcher, Dr Noel Whitaker, a co-author of the new report. "Confirming a cancer-causing role for HPV in some breast cancers establishes the possibility of preventing some breast cancers by vaccination against HPV," he says.

The idea that HPV has an involvement in breast cancer is controversial. Scientific reports from 15 countries around the world have identified the presence of high-risk types of HPV in breast tissue and breast cancer specimens.

But those studies have also showed widely varying results, with the prevalence of HPV-positive breast cancer in ranging from as low as four per cent to as high as 86 per cent, and have been clouded by difficulties in detecting the virus in breast specimens.

As well, the genetic probe technique used polymerase chain reaction (PCR) has been criticized for its propensity for contamination.

The technique is based on taking small genetic samples and rapidly copying them to provide a large enough sample to study.

The UNSW researchers addressed these issues by using a technique (in situ PCR) that avoids cross-contamination and that provides evidence about whether HPV genetic material is present in the nuclei of human breast cancer specimens. They validated their findings by looking for "telltale" changes linked to HPV such as enlarged nucleus surrounded by a characteristic "halo". The researchers are working on a new method that will make testing even quicker, cheaper and simpler.

Globally 1.1 million women were diagnosed with breast cancer and more than 500,000 women lost their life to the disease in 2004. Australia data reveals that 12,265 women were diagnosed with breast cancer in 2005, and 2,618 women died from breast cancer in 2006. During the past quarter century 213,658 Australian women were diagnosed with breast cancer (1982 2005) and 63,632 died from the disease (1981 2006).


'/>"/>

Contact: Dr Noel Whitaker
n.whitaker@unsw.edu.au
61-404-236-953
University of New South Wales
Source:Eurekalert

Related medicine news :

1. Pennsylvania Department of Health Launches Online H1N1 Vaccine Registry
2. Which is the Real Terminator of H1N1 Disease, the Antisepsis or the Vaccine?
3. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
4. IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests
5. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
6. U.S. Childhood Vaccine Rates Good But Could Be Better: CDC
7. IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis
8. HPV Vaccine Could Prevent Many Penile Cancers
9. Study finds promise in combined transplant/vaccine therapy for high-risk leukemia
10. Swine Flu Vaccine Seems Safe in Early Trials
11. Cornell makes cancer vaccine for clinical use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... OR (PRWEB) , ... January 16, 2017 , ... ... author, editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading ... Kent Heckenlively to her nationally syndicated radio program, The Sharon Kleyne Hour Power ...
(Date:1/16/2017)... IL (PRWEB) , ... January 16, 2017 , ... ... (iaedp) organized to provide first-quality education and high-level training standards to an international ... spectrum of eating disorder problems. As a way to further its mission at ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... the latest in 3-D scanning device which is capable of taking digital impressions of ... in dentistry, such as CAD CAM restorations , in terms of speed, efficiency ...
(Date:1/16/2017)... , ... January 16, 2017 , ... NexTec Group has ... group of 100 organizations honored for their accomplishments in the field of midmarket financial ... industry leadership and recognition, and innovation. Selection is not based on revenue and those ...
(Date:1/15/2017)... CINCINNATI, Ohio (PRWEB) , ... January 15, 2017 ... ... their applications, Gensuite’s Community Outreach is a program that strives to better communities ... in each global locations’ community. It also provides the opportunity for team members ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... , January 13, 2017 Constant research ... AIDS will collectively contribute to the demand for western blotting ... a value of US$ 551.0 Mn by 2016 end. Developing ... the most lucrative markets for western blotting, whereas ... globally. ...
(Date:1/13/2017)... YORK , January 13, 2017 ... equities to see how they have fared at yesterday,s ... ), Galena Biopharma Inc. (NASDAQ: GALE ), ... These companies harness cellular and biomolecular processes to develop ... reduce our environmental footprint, feed the hungry, use less ...
Breaking Medicine Technology: